- Alternative procedures for blood and blood components during the COVID-19 public health emergency1
- Amyotrophic lateral sclerosis: developing drugs for treatment1
- Anthrax: developing drugs for prophylaxis of inhalational anthrax1
- Antibacterial therapies for patients with an unmet medical need for the treatment of serious bacterial diseases1
- Antibiotic resistance: more information needed to oversee use of medically important drugs in food animals : report to Congressional requesters1
- Appropriate use of voluntary consensus standards in premarket submissions for medical devices: guidance for industry and Food and Drug Administration staff1
- As funding for BPA research increased, NIEHS followed its peer review process while also exercising its discretion1
- Assessing COVID-19-related symptoms in outpatient adult and adolescent subjects in clinical trials of drugs and biological products for COVID-19 prevention or treatment1
- Assessing user fees under the Biosimilar User Fee Amendments of 20171
- Assessing user fees under the Prescription Drug User Fee Amendments of 20171
- Assessing user fees under the biosimilar user fee amendments of 20171
- Assessment and synthesis of selected Medicaid eligibility, enrollment, and renewal processes and systems in six states1
- Associations between county-level vaccination rates and COVID-19 outcomes among Medicare beneficiaries1
- BCG-unresponsive nonmuscle invasive bladder cancer: developing drugs and biologics for treatment1
- Bacterial risk control strategies for blood collection establishments and transfusion services to enhance the safety and availability of platelets for transfusion1
- Bacterial vaginosis: developing drugs for treatment1
- Basic safety and essential performance of medical electrical equipment, medical electrical systems, and laboratory medical equipment: standards specific information for the Accreditation Scheme for Conformity Assessment (ASCA) Pilot Program : guidance for industry, accreditation bodies, testing laboratories, and Food and Drug Administration staff1
- Best practices for communication between IND sponsors and FDA during drug development: guidance for industry and review staff : good review practice1
- Bioanalytical method validation1
- Biocompatibility testing of medical devices: standards specific information for the Accreditation Scheme for Conformity Assessment (ASCA) Pilot Program : guidance for industry, accreditation bodies, testing laboratories, and Food and Drug Administration staff1